Clinical trial
Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the…
NCT00403442 · Vitreous -Retina- Macula Consultants of New York, Other · Terminated
Key facts
| NCT number | NCT00403442 |
|---|---|
| Title | Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD |
| Official title | Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD |
| Lead sponsor | Vitreous -Retina- Macula Consultants of New York, Other |
| Collaborators | QLT Inc. Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Macular Degeneration |
| Intervention type | Device |
| Interventions | Verteporfin Therapy/ Drug: Bevacizumab |
| Enrollment | 10 |
| Start date | Sep 1, 2006 |
| First posted | Nov 23, 2006 |
| Last update posted | Jul 30, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: